Does hypothyroidism predispose to gold-induced thrombocytopenia?

Area of Science:

• Rheumatology
• Hematology
• Endocrinology

Background:

• Gold therapy is a treatment for rheumatoid arthritis.
• Rheumatoid arthritis is a chronic autoimmune disease causing joint inflammation.
• Thyroid hormone replacement therapy is used for hypothyroidism.

Observation:

• Two patients on gold therapy for rheumatoid arthritis experienced sudden, severe thrombocytopenia (low platelet count).
• Both patients had a history of long-term thyroxine replacement therapy for hypothyroidism.
• Clinical manifestations included spontaneous soft tissue bleeding, epistaxis, and macroscopic hematuria.

Findings:

• Gold therapy can induce acute thrombocytopenia in rheumatoid arthritis patients.
• Pre-existing hypothyroidism may be a risk factor for developing gold-induced thrombocytopenia.
• Hypothyroidism-associated changes might predispose individuals to adverse hematological effects from gold.

Implications:

• Patients with rheumatoid arthritis and hypothyroidism require vigilant monitoring during gold therapy.
• Consideration of thyroid status is crucial when assessing bleeding risks in patients on gold treatment.
• This finding highlights the importance of personalized medicine in managing autoimmune diseases and their treatments.